(A Little) Clarity on Convalescent Plasma for Covid-19.
作者信息
Katz Louis M
机构信息
From the Mississippi Valley Regional Blood Center, Davenport, IA.
出版信息
N Engl J Med. 2021 Feb 18;384(7):666-668. doi: 10.1056/NEJMe2035678. Epub 2021 Jan 13.
Abstract
摘要
相似文献
1
(A Little) Clarity on Convalescent Plasma for Covid-19.
N Engl J Med. 2021 Feb 18;384(7):666-668. doi: 10.1056/NEJMe2035678. Epub 2021 Jan 13.
2
Convalescent plasma for COVID-19 considerations.
Transfus Apher Sci. 2021 Feb;60(1):102927. doi: 10.1016/j.transci.2020.102927. Epub 2020 Aug 27.
3
Covid-19 convalescent plasma and SARS-CoV-2 viral variants.
Transfus Clin Biol. 2021 Aug;28(3):306. doi: 10.1016/j.tracli.2021.05.008. Epub 2021 May 29.
4
Use of Convalescent Plasma in the Management of COVID-19.
Mo Med. 2021 Mar-Apr;118(2):118.
5
Implications of Coronavirus Disease 2019 (COVID-19) Antibody Dynamics for Immunity and Convalescent Plasma Therapy.
Clin Infect Dis. 2021 Aug 2;73(3):e540-e542. doi: 10.1093/cid/ciaa1213.
6
[COVID-19: blood sufficiency versus convalescent plasma?].
Rev Med Chil. 2020 Jun;148(6):721-723. doi: 10.4067/S0034-98872020000600721.
7
Appropriate selection of convalescent plasma donors for COVID-19.
Lancet Infect Dis. 2021 Feb;21(2):168-169. doi: 10.1016/S1473-3099(20)30470-9. Epub 2020 Jun 15.
8
How Safe Is COVID-19 Convalescent Plasma?
Mayo Clin Proc. 2021 Aug;96(8):2279-2281. doi: 10.1016/j.mayocp.2021.06.011. Epub 2021 Jun 25.
9
Correspondence on 'CONVALESCENT plasma for COVID-19'.
Eur J Clin Invest. 2021 Nov;51(11):e13677. doi: 10.1111/eci.13677. Epub 2021 Sep 13.
10
Convalescent plasma therapy in patients with COVID-19.
Transfus Apher Sci. 2021 Feb;60(1):103017. doi: 10.1016/j.transci.2020.103017. Epub 2020 Nov 19.
引用本文的文献
1
Immunogenic Potential of Selected Peptides from SARS-CoV-2 Proteins and Their Ability to Block S1/ACE-2 Binding.
Viruses. 2025 Jan 24;17(2):165. doi: 10.3390/v17020165.
2
Clinical Course and Factors Associated With Hospital Admission and Mortality among Sars-Cov 2 Patients within Nairobi Metropolitan Area.
medRxiv. 2024 May 15:2024.05.15.24307403. doi: 10.1101/2024.05.15.24307403.
3
Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection.
Vaccines (Basel). 2023 Oct 26;11(11):1644. doi: 10.3390/vaccines11111644.
4
COVID-19: An Overview of SARS-CoV-2 Variants-The Current Vaccines and Drug Development.
Biomed Res Int. 2023 Aug 29;2023:1879554. doi: 10.1155/2023/1879554. eCollection 2023.
5
Antiviral Treatment of Coronavirus Disease-2019 Pneumonia.
Clin Chest Med. 2023 Jun;44(2):279-297. doi: 10.1016/j.ccm.2022.11.008. Epub 2022 Nov 28.
6
Protective roles and protective mechanisms of neutralizing antibodies against SARS-CoV-2 infection and their potential clinical implications.
Front Immunol. 2023 Jan 19;14:1055457. doi: 10.3389/fimmu.2023.1055457. eCollection 2023.
7
Pharmacokinetic and Pharmacodynamic Effects of Polyclonal Antibodies against SARS-CoV2 in Mice.
Viruses. 2022 Dec 30;15(1):123. doi: 10.3390/v15010123.
8
Efficacy of COVID-HIGIV in animal models of SARS-CoV-2 infection.
Sci Rep. 2022 Oct 10;12(1):16956. doi: 10.1038/s41598-022-21223-2.
9
Convalescent Plasma for COVID-19: A Single Center Prospective Experience with Serial Antibody Measurements and Review of the Literature.
Pathogens. 2022 Aug 23;11(9):958. doi: 10.3390/pathogens11090958.
10
COVID-19 in Missouri 2020-2021: A Perspective on Origins, Spread & Controversies, Part I.
Mo Med. 2022 Mar-Apr;119(2):98-105.
本文引用的文献
1
Convalescent Plasma Antibody Levels and the Risk of Death from Covid-19.
N Engl J Med. 2021 Mar 18;384(11):1015-1027. doi: 10.1056/NEJMoa2031893. Epub 2021 Jan 13.
2
Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults.
N Engl J Med. 2021 Feb 18;384(7):610-618. doi: 10.1056/NEJMoa2033700. Epub 2021 Jan 6.
3
A Randomized Trial of Convalescent Plasma in Covid-19 Severe Pneumonia.
N Engl J Med. 2021 Feb 18;384(7):619-629. doi: 10.1056/NEJMoa2031304. Epub 2020 Nov 24.
4
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial).
BMJ. 2020 Oct 22;371:m3939. doi: 10.1136/bmj.m3939.
5
Treatment of Coronavirus Disease 2019 Patients with Convalescent Plasma Reveals a Signal of Significantly Decreased Mortality.
Am J Pathol. 2020 Nov;190(11):2290-2303. doi: 10.1016/j.ajpath.2020.08.001. Epub 2020 Aug 11.
6
Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.
JAMA. 2020 Aug 4;324(5):460-470. doi: 10.1001/jama.2020.10044.
7
Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial.
Lancet Respir Med. 2019 Nov;7(11):941-950. doi: 10.1016/S2213-2600(19)30199-7. Epub 2019 Sep 30.
8
The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.
J Infect Dis. 2015 Jan 1;211(1):80-90. doi: 10.1093/infdis/jiu396. Epub 2014 Jul 16.
9
Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?
Ann Intern Med. 2006 Oct 17;145(8):599-609. doi: 10.7326/0003-4819-145-8-200610170-00139. Epub 2006 Aug 29.
Zotero 插件